To evaluate the potential of biomarkers to predict PA/BSA ≥ 16.6 mm/m2 in patients with severe AS before undergoing TAVR, AUROC and YI analyses were again performed on each of the biomarkers (sST2, GDF-15, H-FABP, IGF-BP2, suPAR, BNP, hsTN, cTnI). The gene discussed is NPPB; the disease is aortic valve stenosis.